US20060121096A1 - Veterinary delivery systems and methods of delivering effective agents to animals - Google Patents
Veterinary delivery systems and methods of delivering effective agents to animals Download PDFInfo
- Publication number
- US20060121096A1 US20060121096A1 US11/333,936 US33393606A US2006121096A1 US 20060121096 A1 US20060121096 A1 US 20060121096A1 US 33393606 A US33393606 A US 33393606A US 2006121096 A1 US2006121096 A1 US 2006121096A1
- Authority
- US
- United States
- Prior art keywords
- canceled
- delivery system
- veterinary
- film
- veterinary delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/168—Steroids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Definitions
- the present invention is directed to veterinary care and, more particularly, to veterinary delivery systems and methods of delivering effective agents to animals.
- Effective veterinary care is very important to animal owners as well as the rest of society. Many people own household pets, such as dogs and cats, and often become emotionally attached to those pets. Other animals, such as dogs used for police work and search and rescue operations, race horses, etc, each play a significant role in society. The proper and efficient veterinary care of these and other animals is very important.
- Typical methods of administering pharmaceuticals to animals include vascular injections, muscular injections and oral administration of liquids or pills.
- Disadvantages of these known pharmaceutical delivery methods include difficulty in administration, pain to the animals, difficulty in measuring the dosages when liquids or pills are added to animal feed, since, for example, some time a number of animals will share a common feed container and animals will sometimes try to spit out medicine.
- One aspect of the present invention comprises a veterinary delivery system in the form of a pliable hydrophilic film comprising at least one binder, at least one lubricant, at least one solvent for the binder and lubricant, and an effective amount of at least one effective agent.
- effective agent is meant to include any compound which has an effect upon one or more health properties of the recipient animal.
- effective agents include compounds which are therapeutically active and are designed to treat a symptom of the animal such as illness, bad breath, incontinence, or others discussed below.
- An effective agent can also comprise a compound having cosmetic effects which will change any visual aspect of the animal, such as an agent which is designed to provide a healthier coat.
- Other pharmaceuticals are also included such as pharmaceutical actives, and is not limited to prescription medicines.
- At least one flavorant is also included in a pliable hydrophilic film in order to enhance oral acceptability by the animal.
- films preferably have a moisture content of not greater than about 15% by weight and most preferably have moisture content of about 3-7% by weight.
- the hydrophilic films most preferably have at least one effective agent distributed homogeneously throughout the film.
- the present invention also comprises methods of delivering effective agents wherein a tacky hydrophilic film comprising at least one effective agent is placed within the oral cavity of an animal.
- the various aspects of the present invention relate to veterinary pharmaceutical delivery systems and methods of delivering effective agents to animals.
- the term “animals” is meant to indicate mammals, and to exclude humans.
- the novel methods and delivery systems described herein utilize a pliable, preferably hydrophilic, film which contains an effective amount of at least one effective agent.
- the preferred films of the present invention advantageously become sufficiently sticky upon contact with the mucousal membrane or tongue of an animal such that the film adheres to the animal's tongue or mucousal membrane and generally is difficult to spit out or be dislodged.
- the films are sticky upon contact due to their hydrophilic nature and relatively low initial moisture content.
- preferred embodiments of the present invention also advantageously comprise flavorants which are particularly adapted to be acceptable by the particular animal.
- One embodiment of the present invention comprises a pliable film comprising at least one binding agent, at least one lubricant, a solvent for the binding agent and the lubricant, and an effective amount of at least one effective agent.
- the binding agent provides the structural integrity to the pliable film, either chemically or physically, and may comprise polyvinyl alcohol, methycelluloses such as hydroxypropyl methylcellulose (HPMC) or carboxymethylcellulose, gelatins, starches, either alone or in combination.
- the final film comprises up to about 95% by weight of the binding agent, and preferably about 40% to 90% by weight, more preferably about 50% to 75% by weight.
- the lubricant can comprise one or more of glycerins, glycols such as propylene glycols, oils such as fish oils or vegetable oils, and combinations thereof.
- the lubricant of the final film should generally be not greater than about 45% by weight of the final film, preferably not greater than about 25%, more preferably about 2 to 15% and most preferably about 4 to 8% by weight. Unless otherwise stated in this application, all percentages are by weight and are expressed as a percentage of the final film.
- a solvent such as water or an organic solvent such as ethanol is preferably employed.
- the solvent preferably comprises about 2 to 15% by weight of solvent and most preferably about 3 to 7% by weight. If desired, more than one solvent can be used.
- the effective agents of the present invention can comprise a wide range of therapeutic actives, cosmetic agents and other veterinary pharmaceuticals such an antibiotics, pain relievers, anti-inflammatory agents, anti-viral agents, vaccines, wormers, heart wormers, nutritional supplements, hypothyroidism medication, arthritis medication, incontinence medication, agents for the control of tartar and plaque, pain relievers, agents for treatment of bacterial diseases and coccidiosis, and combinations thereof.
- therapeutic actives such an antibiotics, pain relievers, anti-inflammatory agents, anti-viral agents, vaccines, wormers, heart wormers, nutritional supplements, hypothyroidism medication, arthritis medication, incontinence medication, agents for the control of tartar and plaque, pain relievers, agents for treatment of bacterial diseases and coccidiosis, and combinations thereof.
- the effective agents can comprise antibiotics such as sulfamethoxazole combined with trimethoprim (ditrim), penicillin, amoxicillin, ampicillin, cephalexin, metronidazole, hypothyroidism medication, such as levothyroxine, agents for treatment of bacterial diseases and coccidiosis such as sulfadimethoxine, pain relievers such as buffered aspirin and prednisone, arthritis medication such as glucosamine HCl, chondroitin sulfate extracts (shark cartilage), minerals-calcium, manganese, magnesium, ascorbic acid (vitamin C), wormers and heartwormers such as ivermectin, fenbendazole, milbemycin oxime, filaribits, parental pamoate, toluene, dichlorophene, piperazine, and agents for the control of tartar and plaque such as tetrasodium pryrophosphate
- preferred embodiments comprise flavoring agents such as beef, chicken, liver, bacon, cheese, apple, smoke, fish, mint such as spearmint or peppermint, and combinations thereof and others.
- Various embodiments of the present invention can also comprise fillers to modify the taste, texture, palpability, stickiness, aroma or roughage characteristics of the film.
- Fillers can be readily chosen and can include fillers such as cornmeal, cornstarch, potato starch, bone meal, corn syrup, wheat germ, brewers yeast, xanthan gum, carrageenan and combinations thereof.
- preservatives such as methyl paraben, propylparaben, ethylenediamine-tetraacetic acid (EDTA), stearic acid, diazolidinyl urea, imdiazolidinyl urea, and combinations thereof in order to enhance shelf stability and minimize microbial growth from contamination.
- preservatives such as methyl paraben, propylparaben, ethylenediamine-tetraacetic acid (EDTA), stearic acid, diazolidinyl urea, imdiazolidinyl urea, and combinations thereof in order to enhance shelf stability and minimize microbial growth from contamination.
- the delivery systems of the present invention can advantageously be manufactured on a bulk scale.
- preferred embodiments are manufactured on a weight by weight concentration of the total product. While the following description utilizes water-soluble ingredients, based upon the solubility of the effective agent, the base can be formulated to be either water soluble or non-water soluble.
- Ingredients are individually weighed or otherwise measured. Some formulas require an emulsion to be formed, based on the solubility of the active or other ingredients. Some ingredients may need to be combined in a series of smaller tanks, prior to being added to a larger tank, again depending on solubility, temperature and mixing characteristics. The ingredients are mixed and/or heated accordingly until a homogeneous solution is achieved. Because certain ingredients will require heat to aid dissolution, the tanks can be heated to reduce mixing time and increase ingredient solubility. The bulk can be used hot or cooled based on viscosity and physical characteristics required for the next phase of manufacturing.
- the second step involves the transfer of the bulk evenly and at the desired thickness onto a belt or sheet of material that will be passed into an oven or otherwise treated to remove the majority of the solvent, e.g. water, from the blend.
- the belt itself can be made of a number of different materials including stainless steel, teflon, aluminum, a high temperature chemical resistant polymer, or metal alloy among others.
- the belt's physical dimensions are based on the width of the bulk film roll desired, and the temperature of the oven.
- (1) The bulk can be pumped onto the belt and spread with a blade or brush type device into an even displacement.
- the bulk can be pumped through a slot dye, with a controlled head pressure, e.g. from about 10-200 psi., onto the belt with dimensions that provide an even displacement of liquid bulk.
- the bulk can be sprayed through a series of nozzles onto the belt.
- the bulk can be spread thinly and evenly by mechanical means.
- the bulk can be poured onto the belt and allowed to run or be blown by forced air to an even distribution.
- the conveyor type belt system is set to move the product at a controlled speed to achieve the desired drying of the product. For example, the belt can advance the product from 2 to 35 feet per minute depending on the moisture in the product, drying rate, and the desired thickness.
- the films of the present invention generally should have thicknesses not greater than about 0.05 inches, preferably not greater than about 0.025 inches, and most preferably about 0.0005 to about 0.010 of an inch.
- the belt passes through an oven or other type environmental chamber at a controlled speed, humidity, ventilation, and temperature to eliminate enough of the solvent to produce a film of the desired consistency.
- the belt speed and oven temperature is controlled to avoid any degradation of the components while eliminating enough solvent from the formulation to achieve the desired pliability of the finished film.
- the optimal conditions are typically between about 35° C. and 100° C.
- the result is sheets of film approximately the width of the belt and the desired thickness. This bulk film contains a known percentage of active drug product.
- the physical dimensions of the finished product typically can range in size from about 10-80 millimeters square, depending on the size of the dose to be delivered.
- the films of the present invention can be larger, smaller or a different shape without departing from the scope of the present invention.
- a person administering the dosage preferably places the film on or under the tongue, between the cheek or gum, or on the pallet of the animal where the film will advantageously adhere and begin to dissolve. As the film dissolves, the effective agent is released and absorbed through the mucous membrane in the mouth and/or the gastro-intestinal tract.
- Another aspect of the present invention is a method of delivering an effective agent to an animal comprising the steps of a method of delivering an effective agent to an animal comprising the steps of providing a pliable film comprising at least one binder, at least one lubricant, at least one solvent for said binder and said lubricant, and an effective amount of at least one effective agent; and placing said film within the oral cavity of said animal, e.g. manually.
- These films are preferably hydrophilic.
- the film is placed within the oral cavity of an animal by first placing the film on an insert device and then placing at least a portion of the insert device within the oral cavity of the animal.
- the film can be adhered to the tongue of the animal or to a mucous membrane in the oral cavity.
- Another aspect of the present invention comprises a method of delivering an effective agent utilizing a film, most preferably a hydrophilic film into the oral cavity of an animal.
- a film of the present invention is placed on an insert device and a portion of that insert device is placed within the oral cavity of the animal.
- the insert device can comprise a wooden dowel, a plastic applicator, something edible, such as a carrot or other vegetable matter, a baked item such as a bread stick or pretzel, or can be forced via pressurized air through a hollow tube into the animal's oral cavity.
- a plurality of effective agents are provided within a single film.
- one effective agent is preferably absorbed transbuccally at a faster rate than a second effective agent which is provided in that same film.
- the second effective agent may have time-release properties which, when ingested, provide sustained release over some period of time.
Abstract
A veterinary delivery system in the form of a pliable film comprising at least one binder, at least one lubricant, at least one solvent for the binder and lubricant, and an effective amount of at least one effective agent. According to one embodiment, a flavorant is included in a pliable hydrophilic film in order to enhance oral acceptability by the animal. In other embodiments, the films preferably have a moisture content of about 2-15%, preferably about 3-7% by weight. The hydrophilic films most preferably have at least one effective agent distributed homogeneously throughout the film. Also disclosed are methods of delivering veterinary delivery systems wherein a pliable, hydrophilic film comprising at least one effective agent is placed within the oral cavity of an animal.
Description
- This is a continuation of U.S. Ser. No. 09/344,693 filed Jun. 25, 1999.
- The present invention is directed to veterinary care and, more particularly, to veterinary delivery systems and methods of delivering effective agents to animals.
- Effective veterinary care is very important to animal owners as well as the rest of society. Many people own household pets, such as dogs and cats, and often become emotionally attached to those pets. Other animals, such as dogs used for police work and search and rescue operations, race horses, etc, each play a significant role in society. The proper and efficient veterinary care of these and other animals is very important.
- The administration of pharmaceuticals, such as anti-biotics, anti-inflammatory agents, anti-viral agents, vaccines and wormers, are important to the health of these animals. Typical methods of administering pharmaceuticals to animals include vascular injections, muscular injections and oral administration of liquids or pills. Disadvantages of these known pharmaceutical delivery methods include difficulty in administration, pain to the animals, difficulty in measuring the dosages when liquids or pills are added to animal feed, since, for example, some time a number of animals will share a common feed container and animals will sometimes try to spit out medicine.
- It would therefore be desirable to provide a delivery system for effective agents which is easier to administer. It would also be desirable to provide veterinary delivery systems which have a higher dose delivery accuracy than previous feed-mixed delivery systems.
- It would also be desirable to provide a veterinary pharmaceutical delivery systems that can be at least partially absorbed into the animals vascular system through mucous membranes while other portions are ingested.
- It would also be desirable to provide methods for delivering agents effective in the care of animals which provide quick efficacy, are easier to store, have longer storage shelf lives and which are less prone to being spit out by the animal receiving the effective agent.
- One aspect of the present invention comprises a veterinary delivery system in the form of a pliable hydrophilic film comprising at least one binder, at least one lubricant, at least one solvent for the binder and lubricant, and an effective amount of at least one effective agent. As used herein, the term “effective agent” is meant to include any compound which has an effect upon one or more health properties of the recipient animal. For example, effective agents include compounds which are therapeutically active and are designed to treat a symptom of the animal such as illness, bad breath, incontinence, or others discussed below. An effective agent can also comprise a compound having cosmetic effects which will change any visual aspect of the animal, such as an agent which is designed to provide a healthier coat. Other pharmaceuticals are also included such as pharmaceutical actives, and is not limited to prescription medicines.
- According to another preferred embodiment of the present invention, at least one flavorant is also included in a pliable hydrophilic film in order to enhance oral acceptability by the animal.
- According to another aspect of the present invention, films preferably have a moisture content of not greater than about 15% by weight and most preferably have moisture content of about 3-7% by weight. The hydrophilic films most preferably have at least one effective agent distributed homogeneously throughout the film.
- The present invention also comprises methods of delivering effective agents wherein a tacky hydrophilic film comprising at least one effective agent is placed within the oral cavity of an animal.
- These and other embodiments of the present invention are described in greater detail below.
- The various aspects of the present invention relate to veterinary pharmaceutical delivery systems and methods of delivering effective agents to animals. As used herein, the term “animals” is meant to indicate mammals, and to exclude humans. The novel methods and delivery systems described herein utilize a pliable, preferably hydrophilic, film which contains an effective amount of at least one effective agent. The preferred films of the present invention advantageously become sufficiently sticky upon contact with the mucousal membrane or tongue of an animal such that the film adheres to the animal's tongue or mucousal membrane and generally is difficult to spit out or be dislodged. The films are sticky upon contact due to their hydrophilic nature and relatively low initial moisture content. In order to further enhance the retention of the delivery systems films by the animal, preferred embodiments of the present invention also advantageously comprise flavorants which are particularly adapted to be acceptable by the particular animal.
- One embodiment of the present invention comprises a pliable film comprising at least one binding agent, at least one lubricant, a solvent for the binding agent and the lubricant, and an effective amount of at least one effective agent. The binding agent provides the structural integrity to the pliable film, either chemically or physically, and may comprise polyvinyl alcohol, methycelluloses such as hydroxypropyl methylcellulose (HPMC) or carboxymethylcellulose, gelatins, starches, either alone or in combination. The final film comprises up to about 95% by weight of the binding agent, and preferably about 40% to 90% by weight, more preferably about 50% to 75% by weight.
- The lubricant can comprise one or more of glycerins, glycols such as propylene glycols, oils such as fish oils or vegetable oils, and combinations thereof. The lubricant of the final film should generally be not greater than about 45% by weight of the final film, preferably not greater than about 25%, more preferably about 2 to 15% and most preferably about 4 to 8% by weight. Unless otherwise stated in this application, all percentages are by weight and are expressed as a percentage of the final film.
- In order to properly blend the binding agent and lubricant, a solvent such as water or an organic solvent such as ethanol is preferably employed. In the final film, the solvent preferably comprises about 2 to 15% by weight of solvent and most preferably about 3 to 7% by weight. If desired, more than one solvent can be used.
- The effective agents of the present invention can comprise a wide range of therapeutic actives, cosmetic agents and other veterinary pharmaceuticals such an antibiotics, pain relievers, anti-inflammatory agents, anti-viral agents, vaccines, wormers, heart wormers, nutritional supplements, hypothyroidism medication, arthritis medication, incontinence medication, agents for the control of tartar and plaque, pain relievers, agents for treatment of bacterial diseases and coccidiosis, and combinations thereof. For example, the effective agents can comprise antibiotics such as sulfamethoxazole combined with trimethoprim (ditrim), penicillin, amoxicillin, ampicillin, cephalexin, metronidazole, hypothyroidism medication, such as levothyroxine, agents for treatment of bacterial diseases and coccidiosis such as sulfadimethoxine, pain relievers such as buffered aspirin and prednisone, arthritis medication such as glucosamine HCl, chondroitin sulfate extracts (shark cartilage), minerals-calcium, manganese, magnesium, ascorbic acid (vitamin C), wormers and heartwormers such as ivermectin, fenbendazole, milbemycin oxime, filaribits, parental pamoate, toluene, dichlorophene, piperazine, and agents for the control of tartar and plaque such as tetrasodium pryrophosphate. The amount of the active ingredient employed in the initial mixture will depend upon the desired dosage. According to preferred embodiments of the present invention, the effective agent is preferably homogeneously distributed throughout the film.
- In order to enhance the acceptability of the delivery systems of the present invention, preferred embodiments comprise flavoring agents such as beef, chicken, liver, bacon, cheese, apple, smoke, fish, mint such as spearmint or peppermint, and combinations thereof and others.
- Various embodiments of the present invention can also comprise fillers to modify the taste, texture, palpability, stickiness, aroma or roughage characteristics of the film. Fillers can be readily chosen and can include fillers such as cornmeal, cornstarch, potato starch, bone meal, corn syrup, wheat germ, brewers yeast, xanthan gum, carrageenan and combinations thereof.
- It is also in the scope of the present invention to include preservatives such as methyl paraben, propylparaben, ethylenediamine-tetraacetic acid (EDTA), stearic acid, diazolidinyl urea, imdiazolidinyl urea, and combinations thereof in order to enhance shelf stability and minimize microbial growth from contamination.
- The delivery systems of the present invention can advantageously be manufactured on a bulk scale. In order to achieve the desired concentration of effective agent in the dosage form, preferred embodiments are manufactured on a weight by weight concentration of the total product. While the following description utilizes water-soluble ingredients, based upon the solubility of the effective agent, the base can be formulated to be either water soluble or non-water soluble.
- Ingredients are individually weighed or otherwise measured. Some formulas require an emulsion to be formed, based on the solubility of the active or other ingredients. Some ingredients may need to be combined in a series of smaller tanks, prior to being added to a larger tank, again depending on solubility, temperature and mixing characteristics. The ingredients are mixed and/or heated accordingly until a homogeneous solution is achieved. Because certain ingredients will require heat to aid dissolution, the tanks can be heated to reduce mixing time and increase ingredient solubility. The bulk can be used hot or cooled based on viscosity and physical characteristics required for the next phase of manufacturing.
- The second step involves the transfer of the bulk evenly and at the desired thickness onto a belt or sheet of material that will be passed into an oven or otherwise treated to remove the majority of the solvent, e.g. water, from the blend. The belt itself can be made of a number of different materials including stainless steel, teflon, aluminum, a high temperature chemical resistant polymer, or metal alloy among others. The belt's physical dimensions are based on the width of the bulk film roll desired, and the temperature of the oven. There are a number of ways to cast or spread a bulk solution onto the belt evenly and in a manner which advantageously free from bubbles and striations. The following are some of these methods. (1) The bulk can be pumped onto the belt and spread with a blade or brush type device into an even displacement. (2) The bulk can be pumped through a slot dye, with a controlled head pressure, e.g. from about 10-200 psi., onto the belt with dimensions that provide an even displacement of liquid bulk. (3) The bulk can be sprayed through a series of nozzles onto the belt. (4) The bulk can be spread thinly and evenly by mechanical means. (5) The bulk can be poured onto the belt and allowed to run or be blown by forced air to an even distribution. The conveyor type belt system is set to move the product at a controlled speed to achieve the desired drying of the product. For example, the belt can advance the product from 2 to 35 feet per minute depending on the moisture in the product, drying rate, and the desired thickness. The films of the present invention generally should have thicknesses not greater than about 0.05 inches, preferably not greater than about 0.025 inches, and most preferably about 0.0005 to about 0.010 of an inch.
- The belt passes through an oven or other type environmental chamber at a controlled speed, humidity, ventilation, and temperature to eliminate enough of the solvent to produce a film of the desired consistency. To accomplish this, the belt speed and oven temperature is controlled to avoid any degradation of the components while eliminating enough solvent from the formulation to achieve the desired pliability of the finished film. The optimal conditions are typically between about 35° C. and 100° C. The result is sheets of film approximately the width of the belt and the desired thickness. This bulk film contains a known percentage of active drug product.
- The physical dimensions of the finished product typically can range in size from about 10-80 millimeters square, depending on the size of the dose to be delivered. The films of the present invention can be larger, smaller or a different shape without departing from the scope of the present invention.
- A person administering the dosage preferably places the film on or under the tongue, between the cheek or gum, or on the pallet of the animal where the film will advantageously adhere and begin to dissolve. As the film dissolves, the effective agent is released and absorbed through the mucous membrane in the mouth and/or the gastro-intestinal tract.
- Another aspect of the present invention is a method of delivering an effective agent to an animal comprising the steps of a method of delivering an effective agent to an animal comprising the steps of providing a pliable film comprising at least one binder, at least one lubricant, at least one solvent for said binder and said lubricant, and an effective amount of at least one effective agent; and placing said film within the oral cavity of said animal, e.g. manually. These films are preferably hydrophilic.
- According to a still further embodiment, the film is placed within the oral cavity of an animal by first placing the film on an insert device and then placing at least a portion of the insert device within the oral cavity of the animal. The film can be adhered to the tongue of the animal or to a mucous membrane in the oral cavity.
- Another aspect of the present invention comprises a method of delivering an effective agent utilizing a film, most preferably a hydrophilic film into the oral cavity of an animal. Those skilled in the art will appreciate that the veterinary care provider may not wish to insert his hand into the oral cavity of certain animals. Therefore, according to another aspect of the present invention, a film of the present invention is placed on an insert device and a portion of that insert device is placed within the oral cavity of the animal. The insert device can comprise a wooden dowel, a plastic applicator, something edible, such as a carrot or other vegetable matter, a baked item such as a bread stick or pretzel, or can be forced via pressurized air through a hollow tube into the animal's oral cavity.
- According to another embodiment of the present invention, a plurality of effective agents are provided within a single film. For example, according to one embodiment, one effective agent is preferably absorbed transbuccally at a faster rate than a second effective agent which is provided in that same film. For example, the second effective agent may have time-release properties which, when ingested, provide sustained release over some period of time.
Claims (80)
1. A veterinary delivery system comprising:
a pliable film comprising at least one binder, at least one lubricant, at least one solvent for said binder and said lubricant, and an effective amount of at least one effective agent.
2. A veterinary delivery system according to claim 1 wherein said effective agent is a pharmaceutically active component.
3. A veterinary delivery system according to claim 1 wherein said effective agent is a therapeutic agent.
4. A veterinary delivery system according to claim 1 wherein said effective agent is a cosmetic agent.
5. A veterinary delivery system according to claim 1 wherein said film further comprises a flavorant.
6. A veterinary delivery system according to claim 2 wherein said flavorant is selected from the group consisting of genuine and artificial beef, chicken, liver, bacon, cheese, apple, smoke and fish flavorants, mint flavorants and combinations thereof.
7. A veterinary delivery system according to claim 1 wherein said film has a moisture content of not greater than about 15% by weight.
8. A veterinary delivery system according to claim 1 wherein said film has a moisture content of about 3%-7% by weight.
9. A veterinary delivery system according to claim 1 wherein said film has a moisture content of about 4-6% by weight.
10. A veterinary delivery system according to claim 1 wherein said film has a moisture content of about 4.5%-5.5% by weight.
11. A veterinary delivery system according to claim 1 wherein said lubricant is selected from the group consisting of glycerins, glycols, oils and combinations thereof.
12. A veterinary delivery system according to claim 1 wherein said lubricant comprises propylene glycol.
13. A veterinary delivery system according to claim 1 wherein said lubricant comprises a fish oil.
14. A veterinary delivery system according to claim 1 wherein said lubricant comprises a vegetable oil.
15. A veterinary delivery system according to claim 1 wherein said binder comprises polyvinyl alcohol.
16. A veterinary delivery system according to claim 1 wherein said binder comprises a methylcellulose.
17. A veterinary delivery system according to claim 1 wherein said binder comprises hydroxypropyl methycellulose.
18. A veterinary delivery system according to claim 1 wherein said film further comprises a filler.
19. A veterinary delivery system according to claim 18 wherein said filler is selected from the group consisting of cornmeal, cornstarch, potato starch, bone meal, corn syrup, wheat germ, brewers yeast, xanthan gum, carrageenan and combinations thereof.
20. A veterinary delivery system according to claim 1 wherein said effective agent is selected from the group consisting of antibiotics, pain relievers, anti-inflammatory agents, anti-viral agents, vaccines, wormers, heartwormers, nutritional supplements, hypothyroidism medication, arthritis medication, agents for the control of tartar and plaque, incontinence medication, pain relievers, agents for treatment of bacterial diseases and coccidiosis, nutritional supplements and combinations thereof.
21. A veterinary delivery system according to claim 1 wherein said solvent comprises water.
22. A veterinary delivery system according to claim 1 wherein said solvent comprises an organic solvent.
23. A veterinary delivery system according to claim 22 wherein said solvent comprises ethanol.
24. A veterinary delivery system according to claim 1 wherein said film further comprises at least one preservative.
25. A veterinary delivery system according to claim 24 wherein said preservative is selected from the group consisting of methyl paraben, propylparaben, ethylenediamine-tetraacetic acid (EDTA), stearic acid, diazolidinyl urea, imdiazolidinyl urea, and combinations thereof.
26. A veterinary delivery system according to claim 1 wherein at least one pharmaceutically active component is soluble in said solvent.
27. A veterinary delivery system according to claim 1 wherein at least one pharmaceutically active component is not soluble in said solvent.
28. (canceled)
29. (canceled)
30. (canceled)
31. (canceled)
32. (canceled)
33. (canceled)
34. (canceled)
35. (canceled)
36. (canceled)
37. (canceled)
38. (canceled)
39. (canceled)
40. (canceled)
41. (canceled)
42. A veterinary care delivery system comprising:
a pliable film comprising:
at least one binder;
at least one lubricant;
at least one solvent for said binder and said lubricant;
an effective amount of at least one effective agent; and
at least one flavorant.
43. A veterinary care delivery system according to claim 42 wherein said pliable film is hydrophilic.
44. (canceled)
45. (canceled)
46. (canceled)
47. (canceled)
48. (canceled)
49. (canceled)
50. (canceled)
51. (canceled)
52. (canceled)
53. (canceled)
54. (canceled)
55. (canceled)
56. (canceled)
57. (canceled)
58. (canceled)
59. (canceled)
60. (canceled)
61. (canceled)
62. (canceled)
63. (canceled)
64. (canceled)
65. (canceled)
66. (canceled)
67. (canceled)
68. (canceled)
69. (canceled)
70. A method of delivering an effective agent to an animal comprising the steps of:
providing a pliable film comprising at least one binder, at least one lubricant, at least one solvent for said binder and said lubricant, and an effective amount of at least one effective agent; and
placing said film within the oral cavity of said animal.
71. (canceled)
72. (canceled)
73. (canceled)
74. (canceled)
75. (canceled)
76. (canceled)
77. (canceled)
78. (canceled)
79. (canceled)
80. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/333,936 US20060121096A1 (en) | 1999-06-25 | 2006-01-18 | Veterinary delivery systems and methods of delivering effective agents to animals |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/344,693 US20020076440A1 (en) | 1999-06-25 | 1999-06-25 | Veterinary delivery systems and methods of delivering effective agents to animals |
US43899603A | 2003-05-15 | 2003-05-15 | |
US10/730,712 US7005142B2 (en) | 1999-06-25 | 2003-12-05 | Veterinary delivery systems and methods of delivering effective agents to animals |
US11/333,936 US20060121096A1 (en) | 1999-06-25 | 2006-01-18 | Veterinary delivery systems and methods of delivering effective agents to animals |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/344,693 Continuation US20020076440A1 (en) | 1999-06-25 | 1999-06-25 | Veterinary delivery systems and methods of delivering effective agents to animals |
US10/730,712 Continuation US7005142B2 (en) | 1999-06-25 | 2003-12-05 | Veterinary delivery systems and methods of delivering effective agents to animals |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060121096A1 true US20060121096A1 (en) | 2006-06-08 |
Family
ID=23351594
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/344,693 Abandoned US20020076440A1 (en) | 1999-06-25 | 1999-06-25 | Veterinary delivery systems and methods of delivering effective agents to animals |
US10/730,712 Expired - Fee Related US7005142B2 (en) | 1999-06-25 | 2003-12-05 | Veterinary delivery systems and methods of delivering effective agents to animals |
US11/333,936 Abandoned US20060121096A1 (en) | 1999-06-25 | 2006-01-18 | Veterinary delivery systems and methods of delivering effective agents to animals |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/344,693 Abandoned US20020076440A1 (en) | 1999-06-25 | 1999-06-25 | Veterinary delivery systems and methods of delivering effective agents to animals |
US10/730,712 Expired - Fee Related US7005142B2 (en) | 1999-06-25 | 2003-12-05 | Veterinary delivery systems and methods of delivering effective agents to animals |
Country Status (1)
Country | Link |
---|---|
US (3) | US20020076440A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100251812A1 (en) * | 2006-11-29 | 2010-10-07 | Future Path Medical Llc | Container for physiological fluids |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020076440A1 (en) * | 1999-06-25 | 2002-06-20 | Thomas Leon | Veterinary delivery systems and methods of delivering effective agents to animals |
US20040043061A1 (en) * | 2000-09-15 | 2004-03-04 | Leon Daniel S. | Dissolvable films comprising suspended, non-soluble pharmaceutically active ingredients, apparatus and methods for their manufacture and use |
US8663687B2 (en) * | 2001-10-12 | 2014-03-04 | Monosol Rx, Llc | Film compositions for delivery of actives |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US7666337B2 (en) * | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
US7425292B2 (en) * | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
CA2505796C (en) * | 2002-07-22 | 2012-01-03 | Monosolrx Llc | Packaging and dispensing of rapid dissolve dosage form |
WO2004087084A1 (en) * | 2003-03-26 | 2004-10-14 | The Procter & Gamble Company | Rapidly dissolving edible film compositions with cellulose film forming polymers |
CA2520383C (en) * | 2003-03-26 | 2013-12-17 | The Procter & Gamble Company | Rapidly dissolving edible film compositions with improved film strength and stability |
WO2005018607A1 (en) * | 2003-08-20 | 2005-03-03 | Ajinomoto Co., Inc. | Medicinal preparation having improved dissolution properties |
EP2063864A4 (en) | 2006-09-20 | 2012-03-14 | Monosol Rx Llc | Edible water-soluble film containing a foam reducing flavoring agent |
US20080292683A1 (en) * | 2007-05-24 | 2008-11-27 | Monosolrx, Llc. | Film shreds and delivery system incorporating same |
US8298583B2 (en) * | 2007-10-19 | 2012-10-30 | Monosol Rx, Llc | Film delivery system for tetrahydrolipstatin |
US20100040727A1 (en) * | 2008-08-18 | 2010-02-18 | Monosol Rx, Llc | Method for Improving Uniformity of Content in Edible Film Manufacturing |
US8282954B2 (en) * | 2008-12-15 | 2012-10-09 | Monosol Rx, Llc | Method for manufacturing edible film |
US20100297232A1 (en) * | 2009-05-19 | 2010-11-25 | Monosol Rx, Llc | Ondansetron film compositions |
US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
CA2784587A1 (en) * | 2009-12-28 | 2011-07-28 | Monosol Rx, Llc | Orally administrable film dosage forms containing ondansetron |
US8974826B2 (en) | 2010-06-10 | 2015-03-10 | Monosol Rx, Llc | Nanoparticle film delivery systems |
US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
WO2012103464A2 (en) * | 2011-01-28 | 2012-08-02 | Brian Pulliam | Oral thin film vaccine preparation |
CN102266133A (en) * | 2011-08-03 | 2011-12-07 | 吴江兰瑞特纺织品有限公司 | Children's vesture capable of preventing cold and preparation method of Children's vesture |
EP3452023A1 (en) | 2016-05-05 | 2019-03-13 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4517173A (en) * | 1980-09-26 | 1985-05-14 | Nippon Soda Co. Ltd. | Mucous membrane-adhering film preparation and process for its preparation |
US4713239A (en) * | 1979-05-29 | 1987-12-15 | Vsesojuny Kardiologichesky Nauchny Tsentr Adkaemii Meditsinski Nauk Sssr | Antianginal film and method of treating ischemic heart disease |
US5110605A (en) * | 1990-08-21 | 1992-05-05 | Oramed, Inc. | Calcium polycarbophil-alginate controlled release composition and method |
US5314915A (en) * | 1991-09-25 | 1994-05-24 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
US20040115252A1 (en) * | 1999-06-25 | 2004-06-17 | Thomas Leon | Methods of treating illnesses in non-human mammals |
US7005142B2 (en) * | 1999-06-25 | 2006-02-28 | Thomas Leon | Veterinary delivery systems and methods of delivering effective agents to animals |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8810951D0 (en) * | 1988-05-09 | 1988-06-15 | Innovata Biomed Ltd | Buccal local anaesthetic |
US5458884A (en) * | 1992-09-10 | 1995-10-17 | Britton; Peter | Bioerodible device for administering active ingredients |
-
1999
- 1999-06-25 US US09/344,693 patent/US20020076440A1/en not_active Abandoned
-
2003
- 2003-12-05 US US10/730,712 patent/US7005142B2/en not_active Expired - Fee Related
-
2006
- 2006-01-18 US US11/333,936 patent/US20060121096A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4713239A (en) * | 1979-05-29 | 1987-12-15 | Vsesojuny Kardiologichesky Nauchny Tsentr Adkaemii Meditsinski Nauk Sssr | Antianginal film and method of treating ischemic heart disease |
US4517173A (en) * | 1980-09-26 | 1985-05-14 | Nippon Soda Co. Ltd. | Mucous membrane-adhering film preparation and process for its preparation |
US5110605A (en) * | 1990-08-21 | 1992-05-05 | Oramed, Inc. | Calcium polycarbophil-alginate controlled release composition and method |
US5314915A (en) * | 1991-09-25 | 1994-05-24 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
US20040115252A1 (en) * | 1999-06-25 | 2004-06-17 | Thomas Leon | Methods of treating illnesses in non-human mammals |
US7005142B2 (en) * | 1999-06-25 | 2006-02-28 | Thomas Leon | Veterinary delivery systems and methods of delivering effective agents to animals |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100251812A1 (en) * | 2006-11-29 | 2010-10-07 | Future Path Medical Llc | Container for physiological fluids |
Also Published As
Publication number | Publication date |
---|---|
US20020076440A1 (en) | 2002-06-20 |
US7005142B2 (en) | 2006-02-28 |
US20040115253A1 (en) | 2004-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7005142B2 (en) | Veterinary delivery systems and methods of delivering effective agents to animals | |
US8865240B2 (en) | Process for manufacturing chewable dosage forms for drug delivery and products thereof | |
AU744737B2 (en) | Semi-moist oral delivery system | |
CA2632855C (en) | Process for manufacturing chewable dosage forms for drug delivery and products thereof | |
AU2002250904B2 (en) | Mucoadhesive dispersible pharmaceutical preparation for active-agent dosing in veterinary and human medicine | |
JP5530433B2 (en) | Appetizing drugs for oral administration in solid form | |
JP7223744B2 (en) | Starch-free soft chews for veterinary use | |
KR20060052935A (en) | Palatable ductile chewable veterinary composition | |
JP6290081B2 (en) | Composition for oral administration to animals, production method thereof and use thereof | |
CN104203214A (en) | Soft chewable pharmaceutical products | |
CN101744791A (en) | Method for manufacturing edible film | |
KR101790666B1 (en) | Orally Disintegrating Film for Pet | |
RU2679631C2 (en) | Compositions of grapiprant and methods for using same | |
AU2002337517B2 (en) | Tablet delivery system | |
EP0081896A2 (en) | Waterless thixotropic composition | |
US20200093739A1 (en) | Soft chews with low water activity and methods of manufacturing same | |
US20040115252A1 (en) | Methods of treating illnesses in non-human mammals | |
AU778538B2 (en) | Method and composition for administering a cyclooxygenase-2 inhibitor | |
AU2002337517A1 (en) | Tablet delivery system | |
KR20190008264A (en) | Method for producing molded articles for animal administration | |
CA2883139C (en) | Compositions for oral administration to animals, production methods thereof and uses of same | |
JP2001302500A (en) | Drug preparation for mouth | |
US20110118243A1 (en) | Anti-inflammatory drug delivery system | |
CA2704262A1 (en) | Ingestible film composition | |
WO2023126967A1 (en) | Oral films of antipruritic drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |